These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 16444901)

  • 1. Genetic mouse models of Alzheimer's disease.
    Mineur YS; McLoughlin D; Crusio WE; Sluyter F
    Neural Plast; 2005; 12(4):299-310. PubMed ID: 16444901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1.
    Ohno M; Chang L; Tseng W; Oakley H; Citron M; Klein WL; Vassar R; Disterhoft JF
    Eur J Neurosci; 2006 Jan; 23(1):251-60. PubMed ID: 16420434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimer's disease.
    Kobayashi DT; Chen KS
    Genes Brain Behav; 2005 Apr; 4(3):173-96. PubMed ID: 15810905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. It takes tau to tangle--the molecular biology of Alzheimer's disease.
    Lovestone S
    Trans Med Soc Lond; 2001-2002; 118():54-6. PubMed ID: 16116806
    [No Abstract]   [Full Text] [Related]  

  • 5. Transgenic mouse models of Alzheimer's disease: phenotype and application.
    Higgins GA; Jacobsen H
    Behav Pharmacol; 2003 Sep; 14(5-6):419-38. PubMed ID: 14501255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A decade of modeling Alzheimer's disease in transgenic mice.
    McGowan E; Eriksen J; Hutton M
    Trends Genet; 2006 May; 22(5):281-9. PubMed ID: 16567017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mouse models of Alzheimer's disease: the long and filamentous road.
    Phinney AL; Horne P; Yang J; Janus C; Bergeron C; Westaway D
    Neurol Res; 2003 Sep; 25(6):590-600. PubMed ID: 14503012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetically engineered models relevant to neurodegenerative disorders: their value for understanding disease mechanisms and designing/testing experimental therapeutics.
    Wong PC; Cai H; Borchelt DR; Price DL
    J Mol Neurosci; 2001 Oct; 17(2):233-57. PubMed ID: 11816796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein D modulates amyloid pathology in APP/PS1 Alzheimer's disease mice.
    Li H; Ruberu K; Muñoz SS; Jenner AM; Spiro A; Zhao H; Rassart E; Sanchez D; Ganfornina MD; Karl T; Garner B
    Neurobiol Aging; 2015 May; 36(5):1820-33. PubMed ID: 25784209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic administration of fibroblast growth factor-2 (FGF2) reduces BACE1 expression and amyloid pathology in APP23 mice.
    Katsouri L; Ashraf A; Birch AM; Lee KK; Mirzaei N; Sastre M
    Neurobiol Aging; 2015 Feb; 36(2):821-31. PubMed ID: 25457554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of memory loss in Abeta and tau mouse models.
    Ashe KH
    Biochem Soc Trans; 2005 Aug; 33(Pt 4):591-4. PubMed ID: 16042551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Animal models of Alzheimer's disease and frontotemporal dementia.
    Götz J; Ittner LM
    Nat Rev Neurosci; 2008 Jul; 9(7):532-44. PubMed ID: 18568014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triptolide treatment reduces Alzheimer's disease (AD)-like pathology through inhibition of BACE1 in a transgenic mouse model of AD.
    Wang Q; Xiao B; Cui S; Song H; Qian Y; Dong L; An H; Cui Y; Zhang W; He Y; Zhang J; Yang J; Zhang F; Hu G; Gong X; Yan Z; Zheng Y; Wang X
    Dis Model Mech; 2014 Dec; 7(12):1385-95. PubMed ID: 25481013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cell biological perspective on Alzheimer's disease.
    Annaert W; De Strooper B
    Annu Rev Cell Dev Biol; 2002; 18():25-51. PubMed ID: 12142279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug pipeline in neurodegeneration based on transgenic mice models of Alzheimer's disease.
    Li C; Ebrahimi A; Schluesener H
    Ageing Res Rev; 2013 Jan; 12(1):116-40. PubMed ID: 22982398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. REST/NRSF-induced changes of ChAT protein expression in the neocortex and hippocampus of the 3xTg-AD mouse model for Alzheimer's disease.
    Orta-Salazar E; Aguilar-Vázquez A; Martínez-Coria H; Luquín-De Anda S; Rivera-Cervantes M; Beas-Zarate C; Feria-Velasco A; Díaz-Cintra S
    Life Sci; 2014 Oct; 116(2):83-9. PubMed ID: 25261598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic regulation of BACE1 in Alzheimer's disease patients and in transgenic mice.
    Marques SC; Lemos R; Ferreiro E; Martins M; de Mendonça A; Santana I; Outeiro TF; Pereira CM
    Neuroscience; 2012 Sep; 220():256-66. PubMed ID: 22728099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteomic analysis of serum proteins in triple transgenic Alzheimer's disease mice: implications for identifying biomarkers for use to screen potential candidate therapeutic drugs for early Alzheimer's disease.
    Sui X; Ren X; Huang P; Li S; Ma Q; Ying M; Ni J; Liu J; Yang X
    J Alzheimers Dis; 2014; 40(3):575-86. PubMed ID: 24496070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tau, APP, NCT and BACE1 in lymphocytes through cognitively normal ageing and neuropathology.
    Herrera-Rivero M; Soto-Cid A; Hernández ME; Aranda-Abreu GE
    An Acad Bras Cienc; 2013; 85(4):1489-96. PubMed ID: 24346801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Secretases as therapeutic targets for the treatment of Alzheimer's disease].
    Dejaegere T; de Strooper B
    Verh K Acad Geneeskd Belg; 2004; 66(1):29-58; discussion 58-9. PubMed ID: 15074081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.